BACKGROUND: Elevated serum phosphorus and FGF23 are independent cardiovascular risk factors in patients with chronic kidney disease. In a randomized controlled trial of patients with dyslipidemia assigned to eitherextended release niacin (ERN) alone, ERN combined with the selective prostaglandin D2 receptor subtype 1 inhibitor laropiprant (ERN-L) or placebo, niacin lowered serum phosphorus; however, it is not known if it lowers FGF23 concentrations. METHODS: This is an ancillary study to a multicenter, randomized, double-blind, placebo-controlled trial among patients with dyslipidemia and an estimated glomerular filtration rate (eGFR) of 30-74 ml/min/1.73 m(2). Participants were randomized to ERN-L (n = 162), ERN (n = 97), or placebo (n = 68) in a 3:2:1 ratio for 24 weeks. The primary outcome was a change in serum FGF23 concentrations, and secondary outcomes were changes in other mineral metabolism parameters. RESULTS: Both the ERN and ERN-L groups showed significant declines in serum phosphorus, calcium and calcium·phosphorus product at 24 weeks compared to placebo. A significant decline from baseline (10.9%, p < 0.01) in the serum FGF23 concentration was observed in the ERN group compared to placebo, but not in the ERN-L group compared to placebo (p = 0.36 and 0.97 for ERN-L and placebo, respectively), despite equivalent declines in serum phosphorus. Similarly, the most marked declines in PTH occurred in the ERN-only group versus placebo; no change in PTH was observed in the ERN-L group. CONCLUSIONS: In this ancillary study of hyperlipidemic patients with an eGFR of 30-74 ml/min/1.73 m(2), ERN alone but not in combination with laropiprant lowered FGF23 and PTH concentrations. If confirmed, niacin may provide a novel strategy to decrease phosphorus, FGF23, and PTH concentrations in patients with chronic kidney disease.
RCT Entities:
BACKGROUND: Elevated serum phosphorus and FGF23 are independent cardiovascular risk factors in patients with chronic kidney disease. In a randomized controlled trial of patients with dyslipidemia assigned to either extended release niacin (ERN) alone, ERN combined with the selective prostaglandin D2 receptor subtype 1 inhibitor laropiprant (ERN-L) or placebo, niacin lowered serum phosphorus; however, it is not known if it lowers FGF23 concentrations. METHODS: This is an ancillary study to a multicenter, randomized, double-blind, placebo-controlled trial among patients with dyslipidemia and an estimated glomerular filtration rate (eGFR) of 30-74 ml/min/1.73 m(2). Participants were randomized to ERN-L (n = 162), ERN (n = 97), or placebo (n = 68) in a 3:2:1 ratio for 24 weeks. The primary outcome was a change in serum FGF23 concentrations, and secondary outcomes were changes in other mineral metabolism parameters. RESULTS: Both the ERN and ERN-L groups showed significant declines in serum phosphorus, calcium and calcium·phosphorus product at 24 weeks compared to placebo. A significant decline from baseline (10.9%, p < 0.01) in the serum FGF23 concentration was observed in the ERN group compared to placebo, but not in the ERN-L group compared to placebo (p = 0.36 and 0.97 for ERN-L and placebo, respectively), despite equivalent declines in serum phosphorus. Similarly, the most marked declines in PTH occurred in the ERN-only group versus placebo; no change in PTH was observed in the ERN-L group. CONCLUSIONS: In this ancillary study of hyperlipidemic patients with an eGFR of 30-74 ml/min/1.73 m(2), ERN alone but not in combination with laropiprant lowered FGF23 and PTH concentrations. If confirmed, niacin may provide a novel strategy to decrease phosphorus, FGF23, and PTH concentrations in patients with chronic kidney disease.
Authors: Bryan Kestenbaum; Joshua N Sampson; Kyle D Rudser; Donald J Patterson; Stephen L Seliger; Bessie Young; Donald J Sherrard; Dennis L Andress Journal: J Am Soc Nephrol Date: 2004-12-22 Impact factor: 10.121
Authors: K Katai; H Tanaka; S Tatsumi; Y Fukunaga; K Genjida; K Morita; N Kuboyama; T Suzuki; T Akiba; K Miyamoto; E Takeda Journal: Nephrol Dial Transplant Date: 1999-05 Impact factor: 5.992
Authors: Colin D Chue; Jonathan N Townend; William E Moody; Daniel Zehnder; Nadezhda A Wall; Lorraine Harper; Nicola C Edwards; Richard P Steeds; Charles J Ferro Journal: J Am Soc Nephrol Date: 2013-04-18 Impact factor: 10.121
Authors: Danilo Fliser; Barbara Kollerits; Ulrich Neyer; Donna P Ankerst; Karl Lhotta; Arno Lingenhel; Eberhard Ritz; Florian Kronenberg; Erich Kuen; Paul König; Günter Kraatz; Johannes F E Mann; Gerhard A Müller; Hans Köhler; Peter Riegler Journal: J Am Soc Nephrol Date: 2007-07-26 Impact factor: 10.121
Authors: Rakesh Malhotra; Ronit Katz; Andrew Hoofnagle; Andrew Bostom; Dena E Rifkin; Ruth Mcbride; Jeffrey Probstfield; Geoffrey Block; Joachim H Ix Journal: Clin J Am Soc Nephrol Date: 2017-12-05 Impact factor: 8.237
Authors: Tamara Isakova; Joachim H Ix; Stuart M Sprague; Kalani L Raphael; Linda Fried; Jennifer J Gassman; Dominic Raj; Alfred K Cheung; John W Kusek; Michael F Flessner; Myles Wolf; Geoffrey A Block Journal: J Am Soc Nephrol Date: 2015-05-12 Impact factor: 10.121
Authors: Emma D A Wagener; Nao Souma; Alexander Hodakowski; Carlos Martinez; Patrick Fox; Rupal Mehta; Matthew J O'Brien; Maureen Bolon; Laura Kulik; Guang-Yu Yang; Tamara Isakova Journal: Kidney Int Rep Date: 2017-07-29